• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Klaria Pharma Holding AB: Klaria delårsrapport Q1 2026

Klaria Pharma Holding
Download the release

Klaria delårsrapport Q1 2026 1 januar i-31 mars 2026

Sammanfattning av delårsrapporten

Första kvartalet 2026 Koncernen totalt

- Nettoomsättning 0,1 MSEK (9,0 MSEK)

- Övriga intäkter 0,0 MSEK (0,0 MSEK)

- FoU-kostnader för kvartalet uppgick till 4,9 MSEK (3,4 MSEK)

- Resultat efter skatt uppgick till -8,7 MSEK (-1,6 MSEK)

- Resultat per aktie för kvartalet uppgick till -0,04 SEK (-0,01 SEK)

- Kassaflöde från den löpande verksamheten uppgick till -0,1 MSEK (0,9 MSEK)

- Likvida medel på balansdagen uppgick till 0,3 MSEK (1,5 MSEK)

- Eget kapital per 31 mars uppgick till -20,6 MSEK (1,7 MSEK)

- Eget kapital i moderbolaget per 31 mars uppgick till 86,0 MSEK (75,4 MSEK)